The British Journal of Clinical Pharmacology

Volume 55
2003

Published for
The British Pharmacological Society by
Blackwell Publishing

© 2003, Blackwell Publishing Ltd
Osney Mead, Oxford OX2 0EL
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden MA 02148-5018, USA
54 University Street, Carlton, Victoria 3053, Australia

Other Editorial Offices:
Blackwell Wissenschafts-Verlag GmbH
Kurfürstendamm 57
1707 Berlin
Germany

Blackwell Science KK
MG Kodenmacho Building
7-10 Kodenmacho Nihombashi
Chuo-ku, Tokyo 104
Japan

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01923, USA. 0206-5251/01 $15.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by SNP Best-set Typesetter Ltd., Hong Kong
Printed and Bound by The Charlesworth Group, Huddersfield

Contents

This article is considered particularly suitable for continuing medical education.

Volume 55, Number 1, January 2003

Viewpoint

1 Good clinical practice: a nuisance, a help or a necessity for clinical pharmacology?: *J. Sweatman*

Pharmacokinetics

6 Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria: *B.C. Schwahn, D. Hafner, T. Hohlfeld, N. Balkenhol, M.D. Laryea & U. Wendel*

14 Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability: *E. Arlander, J. Sjövall, J. Sörstad, C. Norsten-Höög & L.L. Gustafsson*

23 Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation: *H. Mulla, F. Nabi, S. Nichani, G. Lawson, R.K. Firmin & D.R. Upton*

32 Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients: *I. Meineke & D. Türck*

Pharmacodynamics

39 Biomarkers for the effects of benzodiazepines in healthy volunteers: *S.J. de Visser, J.P. van der Post, P.P. de Waal, F. Cornet, A.F. Cohen & J.M.A. van Gerven*

Pharmacokinetics/pharmacodynamics

51 Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans: *J. Kirchheiner, I. Meineke, N. Steinbach, C. Meisel, I. Roots & J. Brockmöller*

Pharmacogenetics

62 NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios: *Á. Nyéki, T. Buclin, J. Biollaz & L.A. Decosterd*

68 Polymorphisms in the cytochrome P450 CYP1A2 gene (*CYP1A2*) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism: *C. Sachse, U. Bhambra, G. Smith, T.J. Lightfoot, J.H. Barrett, J. Scollay, R.C. Garner, A.R. Boobis, C.R. Wolf & N.J. Gooderham*

Drug Disposition

77 Diabetes mellitus increases the *in vivo* activity of cytochrome P450 2E1 in humans: *Z. Wang, S.D. Hall, J.F. Maya, L. Li, A. Asghar & J.C. Gorski*

Drug Interactions

86 Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function: *R. Orlando, P. Piccoli, S. De Martin, R. Padrini & P. Palatini*

94 Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects: *K.J. Cooper, P.D. Martin, A.L. Dane, M.J. Warwick, A. Raza & D.W. Schneck*

100 Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers: *U.S. Justesen, N.A. Klitgaard, K. Brosen & C. Pedersen*

Short report

107 MMR vaccine and idiopathic thrombocytopaenic purpura: *C. Black, J.A. Kaye & H. Jick*

Letter

112 Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception: *U.I. Schwarz, B. Büschel & W. Kirch*

Volume 55, Number 2, February 2003

Pharmacokinetics

115 Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers: *R.E. Aarnoutse, J.A.H. Droste, J.J.G. van Oosterhout, P.P. Koopmans, M. Popescu, P. Reiss, Y.A. Hekster & D.M. Burger*

Pharmacodynamics

126 Comparative study of analgesic efficacy and morphine-sparing effect of intramuscular dexketoprofen trometamol with ketoprofen or placebo after major orthopaedic surgery: *M.H. Hanna, K.M. Elliott, M.E. Stuart-Taylor, D.R. Roberts, D. Buggy & G.J. Arthurs*

134 Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans: *R.B. Herman, P.J. Jesudason, A.M. Mustafa, R. Husain, A.M.J. Choy & C.C. Lang*

139 Blood pressure response to conventional and low-dose enalapril in chronic renal failure: *T. Elung-Jensen, J. Heisterberg, A.-L. Kamper, J. Sonne & S. Strandgaard*

Pharmacokinetics/Pharmacodynamics

147 Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation: *N. Frey, C. Laveille, M. Paraire, M. Francillard, N.H.G. Holford & R. Jochemsen*

Pharmacogenetics

158 Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity: *A. Alfirevic, A.C. Stalford, F.J. Vilar, Ed G.L. Wilkins, B.K. Park & M. Pirmohamed*

Pharmacovigilance

166 Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study: *D. Layton, J. Riley, L.V. Wilton & S.A.W. Shakir*

Drug Disposition

175 A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology: *M.G. Soars, H.V. Gelboin, K.W. Krausz & R.J. Riley*

Drug Interactions

182 The effect of ketoconazole on the *in vivo* intestinal permeability of fexofenadine using a regional perfusion technique: *C. Tannergren, T. Knutson, L. Knutson & H. Lennernäs*

191 Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug: *F. Vrtic, W.E. Haefeli, J. Drewe, S. Krähenbühl & M. Wenk*

199 Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers: *K. Gallicano, B. Foster & S. Choudhri*

203 Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients: *S. Bauer, E. Störmer, A. Johne, H. Krüger, K. Budde, H.-H. Neumayer, I. Roots & I. Mai*

Short reports

212 Low-dose atorvastatin therapy does not augment endothelial function in active hypercholesterolaemic males: *M.M. Parnell, J.P.F. Chin-Dusting, J. Starr & D.M. Kaye*

216 A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark: *P. Jepsen, M.V. Skriver, A. Floyd, L. Lipworth, H.C. Schonheyder & H.T. Sorensen*

Volume 55, Number 3, March 2003

Editor's View

223 Features of this month's *Journal*: *J.K. Aronson*

Editorial

225 Complementary medicines, clinical pharmacology and therapeutics: *N. Baber*

Review Article

226 Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality: *J. Barnes*

Clinical Toxicology

234 Glutathione, glutathione-dependent enzymes and antioxidant status in erythrocytes from children treated with high-dose paracetamol: *E. Kozer, S. Evans, J. Barr, R. Greenberg, I. Soriano, M. Bulkowstein, I. Petrov, Z. Chen-Levi, B. Barzilay & M. Berkovitch*

Pharmacokinetics

241 Pharmacokinetics of vanadium in humans after intravenous administration of a vanadium containing albumin solution: *G. Heinemann, B. Fichtl & W. Vogt*

Pharmacodynamics

246 Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization: *R.T.C.E. Robinson, N.D. Harris, R.H. Ireland, A. Lindholm & S.R. Heller*

Pharmacokinetics/Pharmacodynamics

252 Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients: *R. Gieschke, H.-U. Burger, B. Reigner, K.S. Blesch & J.-L. Steimer*

Drug Disposition

264 The distribution and gender difference of CYP3A activity in Chinese subjects: *B. Zhu, Z.-Q. Liu, G.-L. Chen, X.-P. Chen, D.-S. Ou-Yang, L.-S. Wang, S.-L. Huang, Z.-R. Tan & H.-H. Zhou*

270 Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients: *H.S. Lee, B.C. Goh, L. Fan, Y.M. Khoo, L. Wang, R. Lim, A.B. Ong & C. Chua*

Pharmacogenetics

278 Arylamine *N*-acetyltransferase-2 genotypes in the Thai population: *V. Kukongviriyapan, A. Prawan, W. Tassaneeyakul, J. Aiemsa-ard & B. Warasiha*

Therapeutics

282 Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient: *Y.K. Loke, A. Bell & S. Derry*

288 Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation: *C.-C. Yang, S.S. Jick & M.A. Testa*

Clinical Trial Design

299 Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods: *J.-S. Hulot, M. Cucherat, A. Charlesworth, D.J. Van Veldhuisen, J.-C. Corvol, A. Mallet, J.-P. Boissel, J. Hampton & P. Lechat*

Short Reports

307 Low blood selenium concentrations in schizophrenic patients on clozapine: *K.S. Vaddadi, E. Soosai & G. Vaddadi*

310 Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis: *D.K.C. Lee, F.M. Robb, E.J. Sims, G.P. Currie, L.C. McFarlane & B.J. Lipworth*
314 A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol: *P. Rolan, I.J. Terpstra, C. Clarke, F. Mullins & J.N. Visser*
317 Development, implementation and cost-effectiveness of a protocol for review of combination diuretic prescribing: *J.D. Morgan, D.J. Wright, H. Chrystyn, B. George, A.C. Booth & D.J. Shoesmith*
321 Genotyping of four genetic polymorphisms in the *CYP1A2* gene in the Egyptian population: *S.I. Hamdy, M. Hiratsuka, K. Narahara, N. Endo, M. El-Enany, N. Moursi, M.S-E. Ahmed & M. Mizugaki*

Letters to the Editors
325 Concomitant overdosing of other drugs in patients with paracetamol poisoning: *G.K. Isbister, I.M. Whyte, F. Downes, A.H. Dawson & P. McGettigan*
326 Concomitant overdosing of other drugs in patients with paracetamol poisoning: *L.E. Schmidt & K. Dalhoff*

Volume 55, Number 4, April 2003

Editor's View
327 Features of this month's *Journal*: *J.K. Aronson*

Editor's Report
329 The *British Journal of Clinical Pharmacology* Editors' Report for 2002: *J.K. Aronson, M.S. Lennard, J.M. Ritter, N.S. Baber, E.J. Begg*

Review
331 Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safety: *J. Barnes*

Pharmacodynamics
341 Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients: *S. Myou, M. Fujimura, Y. Kamio, T. Hirose, T. Kita, H. Tachibana, Y. Ishiura, K. Watanabe, T. Hashimoto & S. Nakao*
347 Influence of captopril on symptomatic and hormonal responses to hypoglycaemia in humans: *K.M. Ohmanns, E. Deininger, P. Wellhoener, B. Schultes, W. Kern, E. Marx, P. Dominiak, J. Born, H.L. Fehm & A. Peters*
354 An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge: *A.M. Wilson, E.J. Sims, L.C. Orr, F. Robb & B.J. Lipworth*

Pharmacokinetics
360 Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection: *A. Tsubota, Y. Hirose, N. Izumi & H. Kumada*
368 The pharmacokinetics of pioglitazone in patients with impaired renal function: *K. Budde, H.-H. Neumayer, L. Fritsche, W. Sulowicz, T. Stompôr & D. Eckland*

Pharmacokinetics/pharmacodynamics
375 Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease: *S.D. Singh, C. Whale, N. Houghton, P. Daley-Yates, S.M. Kirby & A.A. Woodcock*
382 Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam: *N. Yasui-Furukori, T. Takahata, T. Kondo, K. Mihara, S. Kaneko, & T. Tateishi*

Pharmacoepidemiology
389 Undertreatment of hypercholesterolaemia: a population-based study: *A.K. Mantel-Teeuwisse, W.M.M. Verschuren, O.H. Klungel, D. Kromhout, A.D. Lindemans, J. Avorn, A.J. Porsius & A. de Boer*

Clinical Toxicology
398 Valproate overdose: a comparative cohort study of self poisonings: *G.K. Isbister, C.R. Balit, I.M. Whyte & A. Dawson*

Therapeutics
405 A randomized, double-blind crossover trial of paracetamol 1000 mg four times daily *vs* ibuprofen 600 mg: effect on swelling and other postoperative events after third molar surgery: *G.A. Bjornsson, H.R. Haanæs & L.A. Skoglund*

Letters to the Editors
413 A life-threatening interaction between lithium and celecoxib: *L. Slørdal, S. Samstad, J. Bathen & O. Spigset*
414 Common mutant alleles of *CYP2D6* causing the defect of CYP2D6 enzyme activity in a Japanese population: *A. Ishiguro, T. Kubota, H. Sasaki, Y. Yamada & T. Iga*
415 Antiepileptic drug hypersensitivity syndrome in a patient treated with valproate: *J.C. Arévalo-Lorido, J. Carretero-Gómez, J.C. Bureo-Dacal, C. Montero-Leal & P. Bureo-Dacal*

417 Erratum

418 Proceedings of the British Pharmacological Society Clinical Pharmacology Section 7–10 January 2003

Volume 55, Number 5, May 2003

Proceedings of the Festschrift in Honour of Professor Alasdair M. Breckenridge

451 Professor Alasdair Muir Breckenridge CBE

453 A farewell to Alasdair

458 Progress in clinical pharmacology over the last 20 years: *M. Eichelbaum*

460 Management of severe malaria: implications for research: *K. Marsh*

464 The contribution of clinical pharmacology to antimalarial drug discovery and development: *P. Winstanley*

469 Clinical trials of antiretroviral drugs: the role of the MRC AIDS Therapeutic Trials Committee (ATTC) and the MRC Clinical Trials Unit (CTU): *J. Darbyshire*

473 The role of clinical pharmacology in optimizing antiretroviral therapy: *D.J. Back & S.H. Khoo*

477 NHS R & D achievements and future challenges: *K.L. Woods*

480 Training prescribers: past, present and future: *M. Pearson*

483 Clinical pharmacology and therapeutics into the future: *M.D. Rawlins*

486 Adverse drug reactions: back to the future: *M. Pirmohamed & B.K. Park*

Volume 55, Number 6, June 2003

Editor's View

493 Features of this month's *Journal*: *J.K. Aronson*

Editorial

495 Making tomorrow's doctors better prescribers: *M.D. Rawlins*

Special Article

496 Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow's doctors: *S. Maxwell & T. Walley*

Pharmacodynamics

504 Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients: *Y. Ishiura, M. Fujimura, C. Yamamori, K. Nobata, S. Myou, K. Kurashima, Y. Michishita & T. Takegoshi*

511 Variability of heart rate correction methods for the QT interval: *M. Desai, L. Li, Z. Desta, M. Malik & D. Flockhart*

518 Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension: *M.J.B. Kemme, J.P. vd Post, R.C. Schoemaker, M. Straub, A.F. Cohen & J.M.A. van Gerven*

526 C-peptide has no effect on forearm blood flow during local hyperinsulinaemia in healthy humans: *H. Langenberger, G. Schaller, J. Pleiner, F. Mittermayer, M. Bayerle-Eder & M. Wolzt*

531 Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study: *S. Tsuruoka, M. Wakaumi, K. Sugimoto, T. Saito & A. Fujimura*

538 The effect of motilin on the rectum in healthy volunteers: *I.M.C. Kamerling, J. Burggraaf, A.D. van Haarst, M.F. Oppenhuizen-Duinker, H.C. Schoemaker, I. Biemond, R. Jones, H. Heinzerling, A.F. Cohen & A.A.M. Masclee*

Pharmacokinetics

544 Population pharmacokinetics of levosimendan in patients with congestive heart failure: *E.N. Jonsson, S. Antila, L. McFadyen, L. Lehtonen & M.O. Karlsson*

552 Population pharmacokinetics of netilmicin in short-term prophylactic treatment: *N. Jauregizar, J.A. Wald, A. Astobieta, J.M.R. Sasiain, J.C. Lukas & R. Calvo*

Pharmacogenetics

560 Genotype and allele frequencies of *TPMT*, *NAT2*, *GST*, *SULTIA1* and *MDR-1* in the Egyptian population: *S.I. Hamdy, M. Hiratsuka, K. Narahara, N. Endo, M. El-Enany, N. Moursi, M.S.-E. Ahmed & M. Mizugaki*

Drug Dispostion

570 A novel metabolic pathway of morphine: formation of morphine glucosides in cancer patients: *X.Y. Chen, L.M. Zhao & D.F. Zhong*

579 Influence of age on the enantiomeric disposition of ibuprofen in healthy volunteers: *S.C. Tan, B.K. Patel, S.H.D. Jackson, C.G. Swift & A.J. Hutt*

Drug Interactions

588 Evidence of an interaction between nifedipine and nafcillin in humans: *C.C. Lang, S.K. Jamal, Z. Mohamed, M.R. Mustafa, A.M. Mustafa & T.C. Lee*

Pharmacovigilance

591 Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects: *J.C.F. de Jong, P.B. van den Berg, H. Tobi & L.T.W. de Jong-van den Berg*

596 Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland: *D.N. Bateman, A.M. Good, R. Afshari & C.A. Kelly*

Pharmacoepidemiology

604 Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care: *D. Williams, K. Bennett & J. Feely*

Therapeutics

609 A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics: *G.P. Currie, D.K.C. Lee, O.J. Dempsey, S.J. Fowler, L.M. Cowan & B.J. Lipworth*

Short Reports

616 Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin- treated patients with Type 2 diabetes: a double-blind, crossover study: *P. Dhindsa, K.R. Davis & R. Donnelly*

620 Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by *in vivo* microdialysis: *F. Tomaselli, P. Dittrich, A. Maier, M. Woltsche, V. Matzi, J. Pinter, S. Nuhsbaumer, H. Pinter, J. Smolle & F.M. Smolle-Jüttner*

625 CYP3A5 phenotype-genotype correlations in a British population: *B.P. King, J.B.S. Leathart, E. Mutch, F.M. Williams & A.K. Daly*

630 Disposition of debrisoquine and nortriptyline in Korean subjects in relation to *CYP2D6* genotypes, and comparison with Caucasians: *P. Dalén, M.-L. Dahl, H.-K. Roh, G. Tybring, M. Eichelbaum, G.R. Wilkinson & L. Bertilsson*

635 Polymorphic hydroxylation of perhexiline *in vitro*: *L.B. Sørensen, R.N. Sørensen, J.O. Miners, A.A. Somogyi, N. Grgurinovich & D.J. Birkett*

639 The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis: *D.K.C. Lee, K. Haggart, G.P. Currie, S.D. Anderson & B.J. Lipworth*

643 Erratum

644 Reviewers list

646 Indices for Volume 55